CL2009000905A1 - Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad. - Google Patents
Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad.Info
- Publication number
- CL2009000905A1 CL2009000905A1 CL2009000905A CL2009000905A CL2009000905A1 CL 2009000905 A1 CL2009000905 A1 CL 2009000905A1 CL 2009000905 A CL2009000905 A CL 2009000905A CL 2009000905 A CL2009000905 A CL 2009000905A CL 2009000905 A1 CL2009000905 A1 CL 2009000905A1
- Authority
- CL
- Chile
- Prior art keywords
- anxiety
- treat
- edible composition
- related disorders
- bifidobacterium longum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Wood Science & Technology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Virology (AREA)
Abstract
Composición comestible que comprende bifidobacterium longumatcc baa-999; y su uso para tratar o evitar enfermedades neurodegenerativas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08154550A EP2110028A1 (en) | 2008-04-15 | 2008-04-15 | Bifidobacterium longum and hippocampal BDNF expression |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000905A1 true CL2009000905A1 (es) | 2010-08-20 |
Family
ID=39687058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000905A CL2009000905A1 (es) | 2008-04-15 | 2009-04-15 | Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad. |
Country Status (9)
Country | Link |
---|---|
US (1) | US8343482B2 (es) |
EP (5) | EP2110028A1 (es) |
JP (3) | JP5964586B2 (es) |
CN (1) | CN102065710B (es) |
CL (1) | CL2009000905A1 (es) |
DK (1) | DK3072398T3 (es) |
ES (2) | ES2780389T3 (es) |
TW (1) | TW200948372A (es) |
WO (1) | WO2009127566A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2110028A1 (en) | 2008-04-15 | 2009-10-21 | Nestec S.A. | Bifidobacterium longum and hippocampal BDNF expression |
BRPI0921617A2 (pt) * | 2008-11-03 | 2015-08-18 | Nestec Sa | Composicao nutricional compreendendo probioticos e padroes do sono aperfeicoados |
TR201807143T4 (tr) | 2009-08-25 | 2018-06-21 | Nestec Sa | Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar. |
CA2779418C (en) | 2009-11-11 | 2018-03-20 | Alimentary Health Limited | Probiotic bifidobacterium strain |
JP2013119546A (ja) * | 2011-12-09 | 2013-06-17 | Meiji Co Ltd | 不安及び/又は多動性の改善剤 |
CN110201003A (zh) | 2012-02-29 | 2019-09-06 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
CN104046573B (zh) * | 2013-03-11 | 2017-01-18 | 中国农业大学 | 长双歧杆菌及其应用以及功能食品组合物及其制备方法 |
GB201305708D0 (en) * | 2013-03-28 | 2013-05-15 | Clasado Inc | Novel use |
US10633714B2 (en) | 2013-07-21 | 2020-04-28 | Pendulum Therapeutics, Inc. | Methods and systems for microbiome characterization, monitoring and treatment |
CN104413334A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
CN103789268B (zh) * | 2014-02-21 | 2016-04-27 | 刘洛贤 | 一种分离培养海马神经细胞的方法及其专用培养液 |
US20150305385A1 (en) * | 2014-04-25 | 2015-10-29 | Mead Johnson Nutrition Company | Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics |
JP6234331B2 (ja) * | 2014-06-13 | 2017-11-22 | 森永乳業株式会社 | 統合失調症治療剤 |
JP6382027B2 (ja) * | 2014-08-26 | 2018-08-29 | サンスター株式会社 | ビフィズス菌及びアブラナ科野菜を含有する経口組成物 |
SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
BR112017023636B1 (pt) | 2015-06-11 | 2021-11-03 | Société des Produits Nestlé S.A. | Composição oral |
MX2018001849A (es) * | 2015-08-31 | 2018-05-16 | Nestec Sa | Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo. |
CA2994345A1 (en) * | 2015-08-31 | 2017-03-09 | Nestec S.A. | Methods and compositions using bifidobacterium longum to treat or prevent depressive symptoms |
EP3344269A1 (en) * | 2015-08-31 | 2018-07-11 | Nestec S.A. | Methods and compositions using bifidobacterium longum to optimize breastfeeding |
FR3046908B1 (fr) * | 2016-01-21 | 2019-06-21 | Domes Pharma | Complement alimentaire pour utilisation dans la lutte contre le stress et l'anxiete chez les animaux de compagnie |
JPWO2017130859A1 (ja) * | 2016-01-28 | 2018-11-15 | 森永乳業株式会社 | 神経細胞死抑制剤 |
WO2017155861A1 (en) * | 2016-03-10 | 2017-09-14 | Peachstate Health Management Llc Dba Aeon Clinical Laboratories | Methods of treating substance abuse related diseases or disorders |
JP6353478B2 (ja) * | 2016-03-28 | 2018-07-04 | 日清食品ホールディングス株式会社 | セロトニン分泌促進能力を有するビフィズス菌 |
SG11201808685SA (en) | 2016-04-13 | 2018-11-29 | Meiji Co Ltd | Composition for improving brain function for neonates |
ES2960082T3 (es) | 2016-05-31 | 2024-02-29 | Morinaga Milk Industry Co Ltd | Agente de mejora de función cerebral |
EP3478306B1 (en) * | 2016-07-01 | 2023-11-01 | Société des Produits Nestlé S.A. | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and depression in a mammal |
IT201600084470A1 (it) | 2016-08-10 | 2018-02-10 | Probiotical Spa | Composizione per uso nel trattamento del disturbo depressivo maggiore |
WO2018202657A1 (en) * | 2017-05-05 | 2018-11-08 | Nestec S.A. | Treatment of infant colic |
ES2900380T3 (es) | 2017-08-11 | 2022-03-16 | Biocodex | Saccharomyces boulardii para el tratamiento de los trastornos del ánimo |
WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
WO2019098810A2 (ko) * | 2017-11-20 | 2019-05-23 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
KR102250597B1 (ko) * | 2017-11-20 | 2021-05-11 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
JP7346421B2 (ja) * | 2017-12-19 | 2023-09-19 | プロバイオティカル・エッセ・ピ・ア | 睡眠及び気分障害の治療及び/又は改善における使用のための組成物 |
KR102230571B1 (ko) * | 2018-03-22 | 2021-03-22 | 한국식품연구원 | 비형광성 최종당화산물 억제용 조성물 및 이의 용도 |
WO2020037533A1 (zh) * | 2018-08-22 | 2020-02-27 | 江南大学 | 长双歧杆菌婴儿亚种ccfm687、其发酵食品及其应用 |
JP2020037526A (ja) * | 2018-09-04 | 2020-03-12 | 株式会社明治 | 脳機能を改善するための組成物 |
CN109349645A (zh) * | 2018-10-30 | 2019-02-19 | 广州普维君健药业有限公司 | 益生菌组合物、保健食品及其制备方法和应用 |
CN109364097B (zh) * | 2018-11-05 | 2021-06-29 | 福州大学 | 瓜尔豆胶在制备抗抑郁症药物中的应用 |
CN111202754A (zh) * | 2019-03-11 | 2020-05-29 | 江苏佰澳达生物科技有限公司 | 一种预防和改善老年痴呆症的益生菌组合物及其应用 |
CN111297915B (zh) * | 2019-04-12 | 2021-11-23 | 首都医科大学附属北京友谊医院 | 治疗帕金森病快速眼动期睡眠行为障碍的益生菌组合物、制剂及用途 |
JP7503899B2 (ja) * | 2019-07-24 | 2024-06-21 | 雪印メグミルク株式会社 | 記憶・学習能維持および/または向上用組成物及び組成物を含む食品、医薬品、飼料 |
WO2021025154A1 (ja) | 2019-08-08 | 2021-02-11 | 森永乳業株式会社 | 学童期の記憶能向上のための乳幼児用組成物 |
CN110787190B (zh) * | 2019-12-17 | 2020-06-16 | 杨波 | 一种具有抗衰老作用的复合益生菌组合物及其制法和应用 |
WO2021145113A1 (ja) * | 2020-01-17 | 2021-07-22 | 森永乳業株式会社 | 抗老化用組成物 |
CN111560331B (zh) * | 2020-05-15 | 2021-11-09 | 诺佰克(武汉)生物科技有限公司 | 一株副干酪乳杆菌及其应用 |
WO2022092919A1 (ko) * | 2020-10-29 | 2022-05-05 | 엠테라파마 주식회사 | 신규한 비피도박테리움 롱검 z1 균주 및 이의 용도 |
CN114098084A (zh) * | 2021-04-13 | 2022-03-01 | 中国人民解放军军事科学院军事医学研究院 | 一种缓解长期低剂量辐射暴露所致认知损伤的益生菌组合物及其应用 |
CN113322213B (zh) * | 2021-07-09 | 2022-05-13 | 吉林大学 | 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用 |
CN114634900B (zh) * | 2022-05-18 | 2022-08-19 | 鲁东大学 | 一株屎肠球菌ld-nxy01及其在海马养殖中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM864894A0 (en) * | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
JP2826808B2 (ja) * | 1995-07-14 | 1998-11-18 | カルピス株式会社 | 脳機能改善、学習能力増強および記憶力増強作用を有する機能性食品 |
JP4044630B2 (ja) * | 1996-05-16 | 2008-02-06 | 雪印乳業株式会社 | 脳機能改善剤 |
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
US6444203B2 (en) * | 1999-12-20 | 2002-09-03 | Compagnie Gervais Danone | Administering bacteria to improve sleep |
JP2003252771A (ja) * | 2002-03-04 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 加齢に伴う代謝異常疾患の予防・改善・治療剤 |
JP2004262773A (ja) * | 2003-02-17 | 2004-09-24 | Ryoshoku Kenkyukai | 免疫機能改善を目的としたビフィズス菌製剤 |
US20040265279A1 (en) * | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
WO2005034971A2 (en) * | 2003-10-08 | 2005-04-21 | Masami Moriyama | Antiviral agent |
CN101299934B (zh) * | 2005-10-05 | 2012-08-08 | 雀巢技术公司 | 用于促进追赶生长的营养制剂 |
TR201807470T4 (tr) * | 2005-12-15 | 2018-06-21 | Nestec Sa | Beyin fonksiyonlarını korumak için bileşimler ve yöntemler. |
JP2007169200A (ja) * | 2005-12-21 | 2007-07-05 | Morinaga Milk Ind Co Ltd | インフルエンザ感染予防のための医薬及び飲食品 |
PL1986669T3 (pl) * | 2006-02-15 | 2012-09-28 | Nestec Sa | Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia |
JP2008081434A (ja) * | 2006-09-27 | 2008-04-10 | Univ Of Miyazaki | 気分改善剤 |
EP2110028A1 (en) | 2008-04-15 | 2009-10-21 | Nestec S.A. | Bifidobacterium longum and hippocampal BDNF expression |
WO2010008272A1 (en) | 2008-07-15 | 2010-01-21 | N.V. Nutricia | Treatment of gut motility disorders |
TR201807143T4 (tr) | 2009-08-25 | 2018-06-21 | Nestec Sa | Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar. |
-
2008
- 2008-04-15 EP EP08154550A patent/EP2110028A1/en not_active Withdrawn
-
2009
- 2009-04-08 ES ES18172784T patent/ES2780389T3/es active Active
- 2009-04-08 DK DK16165862.0T patent/DK3072398T3/en active
- 2009-04-08 EP EP16165862.0A patent/EP3072398B1/en not_active Revoked
- 2009-04-08 US US12/937,866 patent/US8343482B2/en active Active
- 2009-04-08 ES ES16165862.0T patent/ES2674276T3/es active Active
- 2009-04-08 EP EP18172784.3A patent/EP3398446B1/en not_active Revoked
- 2009-04-08 JP JP2011504422A patent/JP5964586B2/ja active Active
- 2009-04-08 CN CN200980122395.XA patent/CN102065710B/zh active Active
- 2009-04-08 WO PCT/EP2009/054199 patent/WO2009127566A1/en active Application Filing
- 2009-04-08 EP EP20150410.7A patent/EP3673744A1/en not_active Withdrawn
- 2009-04-08 EP EP09733245A patent/EP2291089A1/en not_active Withdrawn
- 2009-04-15 TW TW098112528A patent/TW200948372A/zh unknown
- 2009-04-15 CL CL2009000905A patent/CL2009000905A1/es unknown
-
2014
- 2014-11-14 JP JP2014231568A patent/JP6114247B2/ja active Active
-
2017
- 2017-03-15 JP JP2017049909A patent/JP6554730B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3072398A1 (en) | 2016-09-28 |
JP2015077133A (ja) | 2015-04-23 |
US8343482B2 (en) | 2013-01-01 |
CN102065710B (zh) | 2018-04-13 |
JP2011517568A (ja) | 2011-06-16 |
EP2291089A1 (en) | 2011-03-09 |
TW200948372A (en) | 2009-12-01 |
EP3673744A1 (en) | 2020-07-01 |
JP5964586B2 (ja) | 2016-08-03 |
ES2780389T3 (es) | 2020-08-25 |
ES2674276T3 (es) | 2018-06-28 |
CN102065710A (zh) | 2011-05-18 |
JP2017160200A (ja) | 2017-09-14 |
EP2110028A1 (en) | 2009-10-21 |
EP3398446A1 (en) | 2018-11-07 |
EP3072398B1 (en) | 2018-05-23 |
JP6114247B2 (ja) | 2017-04-12 |
US20110280837A1 (en) | 2011-11-17 |
JP6554730B2 (ja) | 2019-08-07 |
DK3072398T3 (en) | 2018-08-27 |
WO2009127566A1 (en) | 2009-10-22 |
EP3398446B1 (en) | 2020-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000905A1 (es) | Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad. | |
CL2012000487A1 (es) | Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales. | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
GT201200250A (es) | Ariltriazolonas ligadas a bisarilo y su uso | |
HN2011002406A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
CL2011000891A1 (es) | Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales. | |
GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
CO6551686A2 (es) | Inmunoglobinas con dominio variable dual y usos de las mismas | |
CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
HN2011002037A (es) | Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido | |
CL2011002818A1 (es) | Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios. | |
ECSP13012379A (es) | Pirimidinas y triazinas condensadas y su uso | |
BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
ECSP10010295A (es) | Formulacion de anticuerpo | |
ECSP11011276A (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma. | |
CL2008003407A1 (es) | Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1. | |
CO6280490A2 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
CL2011002835A1 (es) | Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros. | |
PA8846101A1 (es) | Anticuerpos del receptor ii anti-tgf-beta | |
BRPI0820465A2 (pt) | Conjunto picador autocontido para reduzir e classsificar meterial | |
PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso |